#mg dosing group

Related by string. * #mgs [002] . #MG [001] . #mg [001] . #mg [002] . #MG [002] : #mg sodium [001] . Lipitor #mg . #mg dosage [001] . #mg ATC . Thalidomide Pharmion #mg / Dosing . Doser . dosed . doss : Ann Doss Helms . By ERIN DOSS . convenient dosing regimen . optimal dosing regimen / grouping . Groups . groups . grouped : Permissions Group Inc. . NASDAQ OMX Group . Lloyds Banking Group . Nuclear Suppliers Group * *

Related by context. Frequent words. (Click for all words.) 63 multicenter Phase 62 goserelin 62 plus gemcitabine 61 active comparator 61 % CI #.#-#.# [003] 61 plus prednisone 60 metastatic castration resistant 60 metastatic hormone refractory 60 plus methotrexate 60 mg kg dose 60 mg QD 60 phase IIa 60 phase IIb clinical 59 mcg dose 59 GSK# [001] 59 lispro 59 #mg/day [001] 59 mcg kg 59 patients evaluable 59 Engerix B 59 paclitaxel eluting stents 58 tamsulosin 58 plus dexamethasone 58 carboplatin paclitaxel 58 forodesine 58 pertuzumab 58 Ixempra 58 Fludara 58 Pivotal Phase III 58 Phase IIb trials 57 elotuzumab 57 clinically meaningful improvement 57 nab paclitaxel 57 QTc prolongation 57 placebo controlled clinical trials 57 placebo controlled Phase 57 EFAPROXYN 57 Phase IIB 57 median PFS 57 placebo controlled clinical 57 Phase Ib clinical 57 μg kg 57 glatiramer acetate 57 Amrubicin 57 irbesartan 57 chlorambucil 57 double blinded placebo 57 dacarbazine 57 fibrinolysis 57 administered subcutaneously 57 dose titration 57 IIa trial 56 events MACE 56 statistically significant p = 56 Phase 2b study 56 Pivotal Phase 56 PRECiSE 56 FOLFIRI 56 PREZISTA r 56 phase 2a 56 % CI #.#-#.# [007] 56 Torisel 56 #mg dose [003] 56 Phase Ia 56 fluvastatin 56 Diabetic Macular Edema 56 events SAEs 56 Paraplatin 56 Cloretazine R VNP#M 56 relapsed multiple myeloma 56 NLX P# 56 pericardial effusion 56 mg BID 56 prospective observational 56 chemoradiotherapy 56 XELOX 55 MKC# 55 phase IIb 55 FOSRENOL R 55 bendamustine 55 TAXUS p value 55 Phase 2a trial 55 Percutaneous Coronary Intervention 55 complete cytogenetic 55 tirofiban 55 FOLFOX 55 PROMACTA 55 cerebrovascular events 55 mitoxantrone 55 methylnaltrexone 55 IIa clinical trial 55 APTIVUS 55 dose cohorts 55 placebo controlled trials 55 INCB# [001] 55 discontinuations due 55 Phase IIa trial 55 achieved statistical significance 55 neoadjuvant 55 peginterferon alfa 2a 55 EndoTAG TM -1

Back to home page